Literature DB >> 4064866

Specificity of indium-111 granulocyte scanning and fecal excretion measurement in inflammatory bowel disease--an autoradiographic study.

A Keshavarzian, Y E Price, A M Peters, J P Lavender, N A Wright, H J Hodgson.   

Abstract

The validity of 111In granulocyte scanning and fecal excretion measurement, as a reflection of loss of cells into the gastrointestinal tract, was studied using an autoradiographic technique in 11 patients in whom 111In granulocyte scan and colonoscopy were carried out simultaneously. 111In granulocytes were injected 1.5-4 hr prior to colonoscopy, and intraluminal fluid, mucosal brushings, and colonic biopsies were collected during the colonoscopy. In two patients with no histological evidence of inflammatory bowel disease, and four patients with clinically and histologically inactive inflammatory bowel disease, no 111Indium was detected in fluid, brushing, or biopsies. In five patients with active disease, 85% of the 111In activity in colonic fluid was precipitated by low-speed centrifugation. Autoradiography confirmed that the label remained attached to whole granulocytes in colonic fluid and mucosal brushings. Studies on biopsies, at intervals up to 4 1/2 hr following labeled granulocyte injection, demonstrated labeled polymorphonuclear neutrophils (PMNs) on the inflamed epithelial surface, with occasional cells in crypt abscesses by 110 min. We conclude that the techniques of 111In granulocyte scanning and fecal counting in patients with IBD are specifically measuring cell loss; labeled PMNs are capable of migrating through the gastrointestinal mucosa, in active disease, within 2 hr of administration.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4064866     DOI: 10.1007/BF01314050

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  9 in total

1.  A prospective study of the course of Crohn's disease.

Authors:  S Kaufman; B Chalmer; R Heilman; W Beeken
Journal:  Dig Dis Sci       Date:  1979-04       Impact factor: 3.199

2.  Quantitative fecal indium 111-labeled leukocyte excretion in the assessment of disease in Crohn's disease.

Authors:  S H Saverymuttu; A M Peters; J P Lavender; M B Pepys; H J Hodgson; V S Chadwick
Journal:  Gastroenterology       Date:  1983-12       Impact factor: 22.682

3.  Effective dose equivalent from radiopharmaceuticals.

Authors:  L Johansson; S Mattsson; B Nosslin
Journal:  Eur J Nucl Med       Date:  1984

4.  Indium-111 autologous leucocyte scanning: comparison with radiology for imaging the colon in inflammatory bowel disease.

Authors:  S H Saverymuttu; A M Peters; H J Hodgson; V S Chadwick; J P Lavender
Journal:  Br Med J (Clin Res Ed)       Date:  1982-07-24

5.  Detection of protein-losing enteropathy by 111In-Transferrin scanning.

Authors:  S H Saverymuttu; A M Peters; J P Lavender; H J Hodgson
Journal:  Eur J Nucl Med       Date:  1983

6.  111Indium leukocyte scanning in small-bowel Crohn's disease.

Authors:  S H Saverymuttu; A M Peters; H J Hodgson; V S Chadwick; J P Lavender
Journal:  Gastrointest Radiol       Date:  1983

Review 7.  Assessment of drug therapy in inflammatory bowel disease.

Authors:  H J Hodgson
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

8.  The labelling of blood cells in plasma with 111In-tropolonate.

Authors:  H J Danpure; S Osman; F Brady
Journal:  Br J Radiol       Date:  1982-03       Impact factor: 3.039

9.  Lung transit of 111Indium-labelled granulocytes. Relationship to labelling techniques.

Authors:  S H Saverymuttu; A M Peters; H J Danpure; H J Reavy; S Osman; J P Lavender
Journal:  Scand J Haematol       Date:  1983-02
  9 in total
  9 in total

1.  Intestinal accumulation of 111In-granulocytes in patients studied because of occult infection.

Authors:  M T Syrjälä; K Liewendahl; V Valtonen; J Gripenberg
Journal:  Eur J Nucl Med       Date:  1987

Review 2.  Laboratory assessment of inflammatory bowel disease.

Authors:  I T Beck
Journal:  Dig Dis Sci       Date:  1987-12       Impact factor: 3.199

Review 3.  Circulating neutrophils from patients with ulcerative colitis have a normal respiratory burst.

Authors:  J M Haydek; A Keshavarzian
Journal:  Inflammation       Date:  1995-12       Impact factor: 4.092

4.  Induction and activation of adaptive immune populations during acute and chronic phases of a murine model of experimental colitis.

Authors:  Lindsay J Hall; Emilie Faivre; Aoife Quinlan; Fergus Shanahan; Kenneth Nally; Silvia Melgar
Journal:  Dig Dis Sci       Date:  2010-05-14       Impact factor: 3.199

5.  Are activity indices helpful in assessing active intestinal inflammation in Crohn's disease?

Authors:  G Crama-Bohbouth; A S Pena; I Biemond; H W Verspaget; D Blok; J W Arndt; I T Weterman; E K Pauwels; C B Lamers
Journal:  Gut       Date:  1989-09       Impact factor: 23.059

6.  Labelling of leucocytes with technetium-99m exametazime causes in vitro upregulation of granulocyte CD11b without correlation to tissue uptake in vivo.

Authors:  S Almer; O Ljunghusen; J Lundahl
Journal:  Eur J Nucl Med       Date:  1996-06

7.  Diminished neutrophil function in Crohn's disease and ulcerative colitis identified by decreased oxidative metabolism and low superoxide dismutase content.

Authors:  H W Verspaget; A S Peña; I T Weterman; C B Lamers
Journal:  Gut       Date:  1988-02       Impact factor: 23.059

8.  Technetium-99m hexamethyl propylene amine oxime granulocyte scintigraphy in Crohn's disease: diagnostic and clinical relevance.

Authors:  G Sciarretta; A Furno; M Mazzoni; C Basile; P Malaguti
Journal:  Gut       Date:  1993-10       Impact factor: 23.059

9.  Flagellin hypervariable region determines symbiotic properties of commensal Escherichia coli strains.

Authors:  Alex Steimle; Sarah Menz; Annika Bender; Brianna Ball; Alexander N R Weber; Thomas Hagemann; Anna Lange; Jan K Maerz; Raphael Parusel; Lena Michaelis; Andrea Schäfer; Hans Yao; Hanna-Christine Löw; Sina Beier; Mehari Tesfazgi Mebrhatu; Kerstin Gronbach; Samuel Wagner; David Voehringer; Martin Schaller; Birgit Fehrenbacher; Ingo B Autenrieth; Tobias A Oelschlaeger; Julia-Stefanie Frick
Journal:  PLoS Biol       Date:  2019-06-17       Impact factor: 8.029

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.